CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
EXC 001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01037413
NCT01037413Phase 2Completed
CompareCT.gov

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, WITHIN-SUBJECT CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF EXC 001 FOR THE AMELIORATION OF SCARRING FOLLOWING REVISION OF SCARS RESULTING FROM PRIOR BREAST SURGERY IN ADULT FEMALE SUBJECTS

Pfizer·interventional·Posted Dec 23, 2009·Updated Aug 2, 2021

In Brief

A Phase 2 clinical trial evaluating EXC 001 and Placebo for Scar Prevention. Completed, enrolled 25 participants across 5 sites.

Detailed Summary

This study will compare how well EXC 001 works to improve the appearance of scars in subjects undergoing breast scar revision surgery. The study will also evaluate the safety of EXC 001 in healthy adult subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScar Prevention
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 23, 2009
Enrollment StartDec 22, 2009
Primary CompletionApr 9, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.5 years ago

Interventions

EXC 001drug

Multiple intradermal injections of EXC 001 and placebo

Placebodrug

Multiple intradermal injections of EXC 001 and placebo